[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637944":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":7,"responsibleParty":19,"collaborators":7,"id":21,"slug":22,"hasResults":23,"nctId":24,"briefTitle":25,"officialTitle":26,"acronym":7,"eligibilityCriteria":27,"healthyVolunteers":28,"sex":29,"minAge":30,"maxAge":7,"enrollmentInfo":31,"targetDuration":34,"studyType":35,"phases":7,"briefSummary":36,"conditions":37,"keywords":7,"overallStatus":44,"whyStopped":7,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":7},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Jyh-Ming Liou, MD, PhD","CONTACT","+886972651883","jyhmingliou@gmail.com",{"name":15,"role":11,"phone":16,"phoneExt":17,"email":18},"Tzu-Chan Hong, MD, PhD","+886-2-2322-0322","238061","edisonhong77@gmail.com",{"type":20,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100637944","ai-based-risk-prediction-model-for-upper-digestive-tract-cancer-100637944",false,"NCT07605312","AI-Based Risk Prediction Model for Upper Digestive Tract Cancer","Development of Artificial Intelligence Risk Prediction Model for Upper Digestive Tract Cancer Using High Resolution Endoscopic Image, Digital Pathology, Genetics, and Oro-gastro-intestinal Microbiota.","Inclusion Criteria:\n\n* Patients undergoing upper gastrointestinal endoscopy.\n* Patients with at least one of the following conditions or indications:\n\n  * Previous or current Helicobacter pylori infection (confirmed by serology, histopathology, urea breath test, rapid urease test, or stool antigen test);\n  * Dyspeptic symptoms;\n  * Gastroesophageal reflux disease;\n  * History of oral, oropharyngeal, or hypopharyngeal squamous cell carcinoma;\n  * Barrett's esophagus;\n  * Gastric premalignant lesions (intestinal metaplasia or atrophic gastritis);\n  * Gastric subepithelial lesions.\n\nExclusion Criteria:\n\n\\-",true,"ALL","40 Years",{"count":32,"type":33},10000,"ESTIMATED","10 Years","OBSERVATIONAL","Upper digestive tract cancers are often preceded by pre-malignant lesions, but there is limited evidence regarding optimal risk prediction models and screening strategies for disease progression and cancer development. This prospective multicenter cohort study aims to establish a longitudinal database integrating clinical information, endoscopic findings, pathology, genetics, epigenetics, and gastrointestinal microbiota data from subjects undergoing upper digestive tract endoscopy.\n\nThe study will develop explainable artificial intelligence (AI)-based risk prediction models to identify factors associated with disease progression, treatment response, and cancer development. Participants will be followed longitudinally to evaluate changes in lesion severity and clinical outcomes.",[38,39,40,41,42,43],"Gastric Cancer (GC)","Premalignant Lesion","Gastric Intestinal Metaplasia","Atrophic Gastritis","Dysplasia Stomach","Esophageal Cancer (EsC)","NOT_YET_RECRUITING","2026-05-25",{"date":47,"type":48},"2026-05-28","ACTUAL",{"date":50,"type":33},"2026-05-18",{"date":52,"type":33},"2030-05-18",{"name":5,"class":6}]